• Yih Chyn PhanEmail author
  • Bob Yang
Part of the In Clinical Practice book series (ICP)


The common classes of antibiotics used to treat UTIs that clinicians should be familiar with include penicillin, cephalosporin, carbapenems, fluoroquinolones, aminoglycosides, and fosfomycin. These are explored further below and summarised in Table 4.1.


  1. 1.
    Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–64.CrossRefGoogle Scholar
  2. 2.
    Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquinolones: a critical review. Can J Infect Dis. 1999;10(3):207–38.CrossRefGoogle Scholar
  3. 3.
    Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029.CrossRefGoogle Scholar
  4. 4.
    DTB. Fosfomycin for UTIs. Drug Ther Bull. 2016;54:114–7.CrossRefGoogle Scholar
  5. 5.
    Avent ML, Rogers BA, Cheng AC, Athan E, Francis JR, Roberts MJ, Paterson DL, Harris PNA. Fosfomycin: what was old is new again. Intern Med J. 2018 Dec;48(12):1425–9.CrossRefGoogle Scholar
  6. 6.
    Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–47.CrossRefGoogle Scholar
  7. 7.
    Mehta D, Sharma AK. Cephalosporins: a review on imperative class of antibiotics. Invent Rapid Mol Pharmacol. 2016;1:1–6.Google Scholar
  8. 8.
    Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–60.CrossRefGoogle Scholar
  9. 9.
    Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570–84.CrossRefGoogle Scholar
  10. 10.
    Wagenlehner FME, Naber KG. Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis. 2019;19(1):22–3.CrossRefGoogle Scholar
  11. 11.
    Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018;11:1461–72.CrossRefGoogle Scholar
  12. 12.
    Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–28.CrossRefGoogle Scholar
  13. 13.
    Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs. 2018;27(2):193–7.CrossRefGoogle Scholar
  14. 14.
    EAU guidelines. Urological infections. Accessed 1 Jan 2019.
  15. 15.
    NICE guidelines. Urinary tract infection (lower)—women. Accessed 1 Jan 2019.
  16. 16.
    Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200(6):1174–91.CrossRefGoogle Scholar
  17. 17.
    Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;3:CD001209.Google Scholar
  18. 18.
    Price JR, Guran LA, Gregory WT, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;215:548.CrossRefGoogle Scholar
  19. 19.
    Ahmed H, Davies F, Francis N, Farewell D, Butler C, Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5):e015233.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Queen Alexandra HospitalPortsmouthUK
  2. 2.Royal Berkshire HospitalReading, GBUK

Personalised recommendations